Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia

被引：2

作者：

Saussele, Susanne ^{[1
]}

La Rosee, Paul ^{[2
]}

Kiani, Alexander ^{[3
,4
]}

Haverkamp, Wilhelm ^{[5
]}

Jentsch-Ullrich, Kathleen ^{[6
]}

Stegelmann, Frank ^{[7
]}

Rieger, Christina ^{[8
]}

Waller, Cornelius F. ^{[9
,10
]}

Franke, Georg-Nikolaus ^{[11
]}

Junghanss, Christian ^{[12
]}

Kirchmair, Rudolf ^{[13
]}

Theurl, Markus ^{[13
]}

le Coutre, Philipp ^{[14
,15
,16
,17
]}

机构：

[1] Heidelberg Univ, Univ Hosp Mannheim, Dept Haematol & Oncol, Mannheim, Germany

[2] Schwarzwald Baar Klinikum, Klin Innere Med 2, Villingen Schwenningen, Germany

[3] Klinikum Bayreuth GmbH, Med Klin 4, Bayreuth, Germany

[4] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Erlangen, Germany

[5] Charite Univ Med Berlin, Dept Cardiol, Campus Virchow Klinikum, Berlin, Germany

[6] Gemeinschaftspraxis Hamatol & Onkol, Magdeburg, Germany

[7] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany

[8] Hematol & Oncol Germering, Germering, Germany

[9] Freiburg Univ, Internal Med 1, Haematol Oncol & Stem Cell Transplantat, Med Ctr, Freiburg, Germany

[10] Fac Med, Freiburg, Germany

[11] Univ Leipzig, Dept Hematol Cellular Therapies & Hemostaseol, Med Ctr, Leipzig, Germany

[12] Rostock Univ, Med Ctr, Dept Med, Hematol,Oncol,Palliat Med,Clin 3, Rostock, Germany

[13] Med Univ Innsbruck, Univ Hosp Internal Med Cardiol & Angiol, Innsbruck, Austria

[14] Charite Univ Med Berlin, Dept Med Hematol & Oncol, Berlin, Germany

[15] Free Univ Berlin, Berlin, Germany

[16] Humboldt Univ, Berlin, Germany

[17] Berlin Inst Hlth, Berlin, Germany

来源：

ACTA HAEMATOLOGICA | 2024年 / 147卷 / 03期

关键词：

Chronic myeloid leukemia; Ponatinib; Dosing regimens; Cardiovascular management; Consensus paper; EVENTS;

D O I：

10.1159/000533666

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Based on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML, the German consensus paper on ponatinib published in 2020 (Saussele S et al., Acta Haematol. 2020) has been updated in this addendum. Summary: Focus is on the update of efficacy and safety of ponatinib, reflecting the new data set, as well as the update of the benefit-risk assessment and recommendations for ponatinib starting dose in CP-CML - provided that the decision to use ponatinib has already been made. Furthermore, based on OPTIC and additional empirical data, the expert panel collaborated to develop a decision tree for ponatinib dosing, specifically for intolerant and resistant patients. The recommendations on cardiovascular management have also been updated based on the most recent 2021 guidelines of the European Society of Cardiology (ESC) on cardiovascular disease prevention in clinical practice. Key Messages: The OPTIC data confirm the high efficacy of ponatinib in patients with CP-CML and provide the basis for individualized dose adjustment during the course of treatment. (c) 2023 The Author(s). Published by S. Karger AG, Basel

引用

页码：344 / 351

页数：8

共 50 条

[31] Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor [J].

Sanford, David ;

Kantarjian, Hagop ;

Skinner, Jeffrey ;

Jabbour, Elias ;

Cortes, Jorge .

HAEMATOLOGICA, 2015, 100 (12) :E494-E495

[32] Asciminib as a new option in the treatment of chronic myeloid leukemia [J].

Ibis, Betul ;

Tiribelli, Mario ;

Eskazan, Ahmet Emre .

FUTURE ONCOLOGY, 2021, 17 (36) :5003-5005

[33] TREATMENT OF CHRONIC MYELOID LEUKEMIA IN PREGNANCY [J].

Gunes, G. ;

Malkan, U. Y. ;

Isik, A. ;

Eliacik, E. ;

Goker, H. ;

Haznedaroglu, I. C. ;

Ozcebe, O. I. ;

Buyukasik, Y. ;

Sayinalp, N. ;

Aksu, S. .

LEUKEMIA RESEARCH, 2014, 38 :S40-S40

[34] Treatment of chronic myeloid leukemia in 2007 [J].

Labussiere, Helene ;

Hayette, Sandrine ;

Tigaud, Isabelle ;

Michallet, Mauricette ;

Nicolini, Franck-Emmanuel .

BULLETIN DU CANCER, 2007, 94 (10) :863-869

[35] Nilotinib for the treatment of chronic myeloid leukemia [J].

Kim, Theo Daniel ;

Dorken, Bernd ;

le Coutre, Philipp .

EXPERT REVIEW OF HEMATOLOGY, 2008, 1 (01) :29-39

[36] Advances in the Treatment of Chronic Myeloid Leukemia [J].

Mihaila, Romeo G. .

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2024, 19 (01) :1-17

[37] Dasatinib in the Treatment of Chronic Myeloid Leukemia [J].

Gora-Tybor, Joanna ;

Robak, Tadeusz .

CURRENT SIGNAL TRANSDUCTION THERAPY, 2011, 6 (01) :99-105

[38] Treatment options for chronic myeloid leukemia [J].

Tanaka, Maria Florencia ;

Kantarjian, Hagop ;

Cortes, Jorge ;

Ohanian, Maro ;

Jabbour, Elias .

EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (06) :815-828

[39] Dasatinib for the treatment of chronic myeloid leukemia [J].

Fullmer, Amber ;

Kantarjian, Hagop ;

Cortes, Jorge ;

Jabbour, Elias .

EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (03) :253-260

[40] Advances in the treatment of chronic myeloid leukemia [J].

Anna M Eiring ;

Jamshid S Khorashad ;

Kimberly Morley ;

Michael W Deininger .

BMC Medicine, 9

← 1 2 3 4 5 →